My $QURE takes:
1. Think mkt is cautiously handicapping regulatory risk. It went to $70 last fall under assumption accel approval was a sure thing. Not so complacent this time.
But until BLA is accepted or 4Y data I expect it’ll have trouble going much above $50.
